Which Myeloma Therapy for Transplant-Ineligible Patients?

Lenalidomide plus weekly dexamethasone until disease progression was the most effective standard-of-care regimen.

To compare two previously established standard-of-care myeloma regimens, investigators conducted an industry-supported, multinational, randomized, prospective, phase III trial involving 1623 patients with newly diagnosed myeloma not eligible for autologous stem cell transplantation. Patients were randomized to lenalidomide plus weekly dexamethasone (LD) for 18 months; continuous LD until disease progression; or melphalan, prednisone, and thalidomide (MPT) for 18 months. The primary endpoint was progression-free survival (PFS).

Response and survival outcomes at a median follow-up of 37 months are shown in the . Also, grade 3 or 4 neutropenia was more common with MPT (45% of patients) versus LD for 18 months (26%) or continuous LD (28%), …

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Which Myeloma Therapy for Transplant-Ineligible Patients?

Topics

Reviewing Author